Pulmonx Corporation, based in Redwood City, Calif., is focused on developing and marketing minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders.

The company is currently engaged in the design, development and manufacture of products that will improve the effectiveness and benefits of endoscopic lung volume reduction (ELVR) for patients with severe emphysema. The company’s Zephyr^® Endobronchial Valve (EBV) therapy* involves placing small one-way valves in the lung to prevent air from entering the most diseased regions while allowing fluids and trapped air to escape. The goal is to reduce the volume of the diseased portions of the lung, allowing increased ventilation to healthier areas of the lung.

Pulmonx takes a unique approach to treating emphysema by providing an assessment tool for optimal targeting of lung volume reduction therapies. The Chartis^® Pulmonary Assessment System is comprised of a balloon catheter and a simple, easy-to-use console which characterizes airflow within lung regions. The goal is to select the appropriate patient and lung region for optimal treatment.

The company has CE mark for the Zephyr EBV and the Chartis System. The company has 510(k) marketing clearance for the Chartis System in the United States.

*Investigational device in the United States. Limited by U.S. law to investigational use.